Key result
Fitbit Inspire shows moderate mid-exercise heart rate agreement with Polar H10 but overestimates peak rates.
Why the study?
Chest-worn monitors pose feasibility challenges in community and unsupervised settings, warranting evaluation of consumer wearables for measuring exercise heart rate in breast cancer survivors.
Does the Fitbit Inspire HR accurately measure heart rate compared to the Polar H10 chest monitor in breast cancer survivors during an exercise program?
RCT (n=14)
Randomized
Yes
Does the Fitbit Inspire HR accurately measure heart rate compared to the Polar H10 chest monitor in breast cancer survivors during an exercise program?
The Fitbit Inspire HR showed variable agreement with a chest strap monitor during exercise in breast cancer survivors, overestimating heart rate at peak intensity which may pose safety risks.
Answers are grounded in this paper and cite their sources.
Overestimation at peak may limit Fitbit use for intensity guidance in survivors; leaves open need for validation before clinical adoption.
BACKGROUND Exercise intensity (eg, target heart rate [HR]) is a fundamental component of exercise prescription to elicit health benefits in cancer survivors. Despite the validity of chest-worn monitors, their feasibility in community and unsupervised exercise settings may be challenging. As wearable technology continues to improve, consumer-based wearable sensors may represent an accessible alternative to traditional monitoring, offering additional advantages. OBJECTIVE The purpose of this study was to examine the agreement between the Polar H10 chest monitor and Fitbit Inspire HR for HR measurement in breast cancer survivors enrolled in the intervention arm of a randomized, pilot exercise trial. METHODS Participants included breast cancer survivors (N=14; aged 38-72 years) randomized to a 12-week aerobic exercise program. This program consisted of three 60-minute, moderate-intensity walking sessions per week, either in small groups or one-on-one, facilitated by a certified exercise physiologist and held at local community fitness centers. As originally designed, the exercise prescription included 36 supervised sessions at a fitness center. However, due to the COVID-19 pandemic, the number of supervised sessions varied depending on whether participants enrolled before or after March 2020. During each exercise session, HR (in beats per minute) was concurrently measured via a Polar H10 chest monitor and a wrist-worn Fitbit Inspire HR at 5 stages: pre-exercise rest; midpoint of warm-up; midpoint of exercise session; midpoint of cool-down; and postexercise recovery. The exercise physiologist recorded the participant’s HR from each device at the midpoint of each stage. HR agreement between the Polar H10 and Fitbit Inspire HR was assessed using Lin concordance correlation coefficient (rc) with a 95% CI. Lin rc ranges from 0 to 1.00, with 0 indicating no concordance and 1.00 indicating perfect concordance. Relative error rates were calculated to examine differences across exercise session stages. RESULTS Data were available for 200 supervised sessions across the sample (session per participant: mean 13.33, SD 13.7). By exercise session stage, agreement between the Polar H10 monitor and the Fitbit was highest during pre-exercise seated rest (rc=0.76, 95% CI 0.70-0.81) and postexercise seated recovery (rc=0.89, 95% CI 0.86-0.92), followed by the midpoint of exercise (rc=0.63, 95% CI 0.55-0.70) and cool-down (rc=0.68, 95% CI 0.60-0.74). The agreement was lowest during warm-up (rc=0.39, 95% CI 0.27-0.49). Relative error rates ranged from –3.91% to 3.09% and were greatest during warm-up (relative error rate: mean –3.91, SD 11.92%). CONCLUSIONS The Fitbit overestimated HR during peak exercise intensity, posing risks for overexercising, which may not be safe for breast cancer survivors’ fitness levels. While the Fitbit Inspire HR may be used to estimate exercise HR, precautions are needed when considering participant safety and data interpretation. CLINICALTRIAL Clinicaltrials.gov NCT03980626; https://clinicaltrials.gov/study/NCT03980626?term=NCT03980626&rank=1
No takes yet. Share an insight, caveat, or question.
Page et al. (2023) conducted an RCT in Breast cancer (n=14). Fitbit Inspire HR vs. Polar H10 chest monitor was evaluated on Heart rate agreement between the Polar H10 and Fitbit Inspire HR at the midpoint of exercise (rc 0.63, 95% CI 0.55-0.70). The Fitbit Inspire HR demonstrated moderate heart rate agreement with the Polar H10 chest monitor during the midpoint of exercise but overestimated peak heart rate.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: